Abstract: A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

Abstract: The use of a combination of photodynamic therapy and an anti-VEGF agent in the treatment of conditions characterized by unwanted choroidal neovasculature is described. These conditions include wet age-related macular degeneration Preferred anti-VEGF agents are antibodies such as bevacizumab or ranibizumab Photosensitizers may be selected from green porphyrins such as BPD-MA (verteporfin) and the photodynamic activation of the photo sensitizer may be accomplished using a reduced fluence rate. The use may further comprises an anti-inflammatory agent such as dexamethasone.

Abstract: A method for converting thermal energy to chemical energy by reducing a reactive oxide substrate at a constant temperature under a first atmosphere with a lower oxygen partial pressure, and then contacting the reduced oxide at the same temperature with a second atmosphere with a higher oxygen partial pressure, during which oxygen is driven into the reduced oxide by the oxygen chemical potential difference between the two atmospheres, thereby leaving fuel behind, i.e. producing fuel. A method for preparing the reactive oxide substrate by using liquid media as a binder and pore former and heating the mixture of the reactive oxide and the liquid media, thereby forming the reactive oxide substrate.

Abstract: A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

Abstract: A foldable safety handrail assembly includes a mounting bracket, a fixing sleeve mounted on the mounting bracket, a release sleeve mounted on the mounting bracket and having a release groove, a rail having a pivot tube which has a first locking groove and a second locking groove, a locking tube extending through the fixing sleeve, the pivot tube and the release sleeve and having a limit slot, a locking member mounted in the limit slot and detachably locked in the first locking groove or the second locking groove, a control member mounted in the locking tube to move the locking member, and a push knob mounted on and pushing the control member. Thus, the user only needs to push the push knob to unlock and fold the rail so that the rail can be unlocked and folded easily and quickly.

Abstract: A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through an upper punctum and into an upper lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a lower punctum and into a lower lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

Abstract: A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

Abstract: A foldable safety handrail assembly includes a mounting bracket, a fixing sleeve mounted on the mounting bracket, a release sleeve mounted on the mounting bracket and having a release groove, a rail having a pivot tube which has a first locking groove and a second locking groove, a locking tube extending through the fixing sleeve, the pivot tube and the release sleeve and having a limit slot, a locking member mounted in the limit slot and detachably locked in the first locking groove or the second locking groove, a control member mounted in the locking tube to move the locking member, and a push knob mounted on and pushing the control member. Thus, the user only needs to push the push knob to unlock and fold the rail so that the rail can be unlocked and folded easily and quickly.

Abstract: The use of a combination of photodynamic therapy and an anti-VEGF agent in the treatment of conditions characterized by unwanted choroidal neovasculature is described. These conditions include wet age-related macular degeneration Preferred anti-VEGF agents are antibodies such as bevacizumab or ranibizumab Photosensitizers may be selected from green porphyrins such as BPD-MA (verteporfin) and the photodynamic activation of the photo sensitizer may be accomplished using a reduced fluence rate. The use may further comprises an anti-inflammatory agent such as dexamethasone.

Abstract: The invention relates to the selection and treatment of subjects afflicted with occult choroidal neovascular lesions, including subjects with age-related macular degeneration, by use of photo dynamic therapy (PDT).

Abstract: A system for correcting quality problems includes a server (1), a database (2), and a plurality of client terminals (4) connected to the server through a network (3). The database stores data used or generated in utilizing the system. Each client terminal provides an interactive user interface for quality control operators to perform corrective actions. The server comprises: a data receiving module (12) for receiving confirmations and responses from the client terminals through the network; a data transmitting module (13) for transmitting initial corrective action reports generated by the server to corresponding client terminals, for operators located at the client terminals to reply to the initial corrective action reports; and a CAR (corrective action report) generating module (14) for integrating all data received by the data receiving module and automatically generating formal corrective action reports. A related method for correcting quality problems is also disclosed.

Abstract: The invention relates to the selection and treatment of subjects afflicted with occult choroidal neovascular lesions, including subjects with age-related macular degeneration, by use of photo dynamic therapy (PDT).